Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

The formation of fibrils can also result in products with lower strengths than expected or indicated on the label, it says. Novo Nordisk made a similar case for semaglutide in a petition to the ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...

As per its FDA label, Ozempic is also indicated to reduce the risk of major adverse cardiovascular events in adults with T2D and established heart disease. Novo Nordisk is eyeing up further ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Danish pharma major Novo Nordisk has announced the appointment of Sebnem Avsar Tuna as the new general manager (GM) of its UK ...

See the Zacks Earnings Calendar to stay ahead of market-making news. In the past 60 days, the Zacks Consensus Estimate for Novo Nordisk’s 2024 earnings per share (EPS) declined from $3.28 to $3. ...